Semaglutide / Cagrilintide Blend combines a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide) to target multiple pathways in appetite regulation and metabolic control. Research suggests this pairing may enhance satiety, reduce food intake, slow gastric emptying, and promote significant weight loss while improving glucose tolerance and supporting cardiovascular health.